Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical data trend for Pharmaron Beijing Co's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:03759 vs VRTX, REGN, RVMD: FCF Margin % Comparison
For the Biotechnology subindustry, Pharmaron Beijing Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmaron Beijing Co FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharmaron Beijing Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Pharmaron Beijing Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmaron Beijing Co (HKSE:03759) has a FCF Margin % of -7.69% as of Jun. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pharmaron Beijing Co and its competitors. According to the industry distribution chart, Pharmaron Beijing Co ranks #225 out of 957 companies in the Biotechnology industry, placing it in the top 23.5%.
Is Pharmaron Beijing Co's FCF Margin % too high?
Pharmaron Beijing Co's current FCF Margin % is -7.69%. Based on the distribution chart, Pharmaron Beijing Co ranks #225 out of 957 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharmaron Beijing Co has a GF Score™ of 90/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmaron Beijing Co's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmaron Beijing Co ranks #225 out of 957 companies for FCF Margin %. This places Pharmaron Beijing Co in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Pharmaron Beijing Co and its competitors. Pharmaron Beijing Co's current FCF Margin % is -7.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmaron Beijing Co stock overvalued right now?
Based on GuruFocus' analysis, Pharmaron Beijing Co (HKSE:03759) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$23.31, compared to a current price of HK$33.20 — trading 42.4% above its estimated fair value. The current FCF Margin % is -7.69%. Pharmaron Beijing Co's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Pharmaron Beijing Co (HKSE:03759), the current FCF Margin % is -7.69% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmaron Beijing Co (HKSE:03759) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmaron Beijing Co stock appears to be overvalued.
The current stock price of HK$33.20 is trading 42.4% above its estimated GF Value™ of HK$23.31.
GuruFocus considers Pharmaron Beijing Co to be Significantly Overvalued.
Key valuation signals for HKSE:03759:
FCF Margin %: -7.69%
GF Value™: HK$23.31 vs. price of HK$33.20 (42.4% above fair value)
No single metric tells the full story. See the HKSE:03759 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmaron Beijing Co Ltd is a research and development service company supporting the life science industry. The company offers drug research and development service capabilities, ranging from synthetic, medicinal, and analytical chemistry, biology, DMPK, pharmacology, drug safety assessment, radiochemistry, and isotopically labelled metabolism, chemical and pharmaceutical development to clinical development. Its operating segment includes Laboratory services; CMC (small molecule CDMO) services, Clinical development services, and biologics and CGT services. It generates maximum revenue from the Laboratory services segment.
90GF Score
Get the complete analysis for HKSE:03759
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03759 has been successfully added to your 
